
Hyloris Pharmaceuticals SA
XBRU:HYL

Intrinsic Value
The intrinsic value of one
HYL
stock under the Base Case scenario is
19.907
EUR.
Compared to the current market price of 6.699 EUR,
Hyloris Pharmaceuticals SA
is
Undervalued by 66%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Hyloris Pharmaceuticals SA
Fundamental Analysis


Revenue & Expenses Breakdown
Hyloris Pharmaceuticals SA
Balance Sheet Decomposition
Hyloris Pharmaceuticals SA
Current Assets | 32.8m |
Cash & Short-Term Investments | 28m |
Receivables | 4.4m |
Other Current Assets | 454k |
Non-Current Assets | 12.7m |
Long-Term Investments | 4.8m |
PP&E | 2.1m |
Intangibles | 3.8m |
Other Non-Current Assets | 2m |
Free Cash Flow Analysis
Hyloris Pharmaceuticals SA
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Hyloris Pharmaceuticals SA
Revenue
|
5.1m
EUR
|
Cost of Revenue
|
-155k
EUR
|
Gross Profit
|
4.9m
EUR
|
Operating Expenses
|
-17.7m
EUR
|
Operating Income
|
-12.8m
EUR
|
Other Expenses
|
531k
EUR
|
Net Income
|
-12.2m
EUR
|
HYL Profitability Score
Profitability Due Diligence
Hyloris Pharmaceuticals SA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Score
Hyloris Pharmaceuticals SA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
HYL Solvency Score
Solvency Due Diligence
Hyloris Pharmaceuticals SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Score
Hyloris Pharmaceuticals SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HYL Price Targets Summary
Hyloris Pharmaceuticals SA
According to Wall Street analysts, the average 1-year price target for
HYL
is 13.94 EUR
with a low forecast of 5.05 EUR and a high forecast of 21 EUR.
Dividends
Current shareholder yield for HYL is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
HYL
stock under the Base Case scenario is
19.907
EUR.
Compared to the current market price of 6.699 EUR,
Hyloris Pharmaceuticals SA
is
Undervalued by 66%.